Endoglin (CD105): A review of its role in angiogenesis and tumor diagnosis, progression and therapy

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2283-2290

  Nassiri, Farshad ^a   Cusimano, Michael D ^a   Scheithauer, Bernd W ^b   Rotondo, Fabio ^a   Fazio, Alessandra ^a   Yousef, George M ^a   Syro, Luis V ^c   Kovacs, Kalman ^a   Lloyd, Ricardo V ^d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MAYO CLINIC   (United States)

^c HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^d University of Wisconsin Health   (United States)

Author keywords

Angiogenesis; Cancer; CD105; Endoglin; Review; Tumor

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ANTIENDOGLIN MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CCAAT ENHANCER BINDING PROTEIN; CD31 ANTIGEN; CYCLOOXYGENASE 2 INHIBITOR; ENDOGLIN; INTERLEUKIN 1 RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; SMAD PROTEIN; STAT1 PROTEIN; TATA BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTERIOVENOUS MALFORMATION; BLEEDING; CANCER GROWTH; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CHROMOSOME 9Q; DOWN REGULATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE MUTATION; GLYCOSYLATION; HALF LIFE TIME; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MELANOMA; METASTASIS; MOLECULAR CLONING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE C MYC; PHASE 1 CLINICAL TRIAL (TOPIC); PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENDU OSLER WEBER DISEASE; REVIEW; SCINTIGRAPHY; T LYMPHOCYTE; TISSUE DISTRIBUTION; TUMOR DIAGNOSIS; TUMOR GROWTH; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; VASCULARIZATION;

ANIMALS; ANTIGENS, CD; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE;

EID: 79960462574     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Quackenbush EJ and Letarte M: Identification of several cell surface proteins of non-T, non-B acute lymphoblastic leukemia by using monoclonal antibodies. J Immunol 134: 1276-1285, 1985. (Pubitemid 15158627)
2. Wong SH, Hamel L, Chevalier S and Philip A: Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. Eur J Biochem 267: 5550-5560, 2000.
3. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES and Thorpe PE: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1: 1623-1634, 1995.
4. Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A, Sedlacek HH, Muller R and Adamkiewicz J: Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 81: 568-572, 1999. (Pubitemid 29203054)
5. Wikstrom P, Lissbrant IF, Stattin P, Egevad L and Bergh A: Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51: 268-275, 2002. (Pubitemid 34556377)
6. Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, Nicotra MR, Natali PG, Altomonte M and Maio M: Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 6: 2037-2043, 2000.
7. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM and Bundred N: Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59: 856-861, 1999. (Pubitemid 29086739)
8. Wang JM, Kumar S, Pye D, Haboubi N and al-Nakib L: Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J Natl Cancer Inst 86: 386-388, 1994. (Pubitemid 24076881)
9. Denekamp J: Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 9: 267-282, 1990.
10. Fonsatti E, Altomonte M, Nicotra MR, Natali PG and Maio M: Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 22: 6557-6563, 2003. (Pubitemid 37372335)
11. Gougos A and Letarte M: Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 141: 1925-1933, 1988.
12. Gougos A and Letarte M: Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265: 8361-8364, 1990.
13. St-Jacques S, Forte M, Lye SJ and Letarte M: Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol Reprod 51: 405-413, 1994. (Pubitemid 24297612)
14. Koleva RI, Conley BA, Romero D, Riley KS, Marto JA, Lux A and Vary CP: Endoglin structure and function: Determinants of endoglin phosphorylation by transforming growth factor-beta receptors. J Biol Chem 281: 25110-25123, 2006. (Pubitemid 44401898)
15. Bellon T, Corbi A, Lastres P, Cales C, Cebrian M, Vera S, Cheifetz S, Massague J, Letarte M and Bernabeu C: Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 23: 2340-2345, 1993. (Pubitemid 23265903)
16. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J and Letarte M: Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267: 19027-19030, 1992.
17. Guerrero-Esteo M, Sanchez-Eisner T, Letamendia A and Bernabeu C: Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem 277: 29197-29209, 2002.
18. Lastres P, Martin-Perez J, Langa C and Bernabeu C: Phosphorylation of the human-transforming growth factor-beta-binding protein endoglin. Biochem J 301(Pt 3): 765-768, 1994.
19. Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra MR, Coral S, Natali PG and Maio M: Endoglin: An accessory component of the TGF-beta-binding receptor complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 188: 1-7, 2001. (Pubitemid 32476491)
20. Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N and Kumar S: Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 89: 122-126, 2000.
21. Fernandez-Ruiz E, St-Jacques S, Bellon T, Letarte M and Bernabeu C: Assignment of the human endoglin gene (END) to 9q34→qter. Cytogenet Cell Genet 64: 204-207, 1993. (Pubitemid 23309620)
22. McAllister KA, Baldwin MA, Thukkani AK, Gallione CJ, Berg JN, Porteous ME, Guttmacher AE and Marchuk DA: Six novel mutations in the endoglin gene in hereditary hemorrhagic telangiectasia type 1 suggest a dominant-negative effect of receptor function. Hum Mol Genet 4: 1983-1985, 1995.
23. Shovlin CL, Hughes JM, Scott J, Seidman CE and Seidman JG: Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet 61: 68-79, 1997. (Pubitemid 27323325)
24. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB and Wendel DP: Defective angiogenesis in mice lacking endoglin. Science 284: 1534-1537, 1999.
25. Rius C, Smith JD, Almendro N, Langa C, Botella LM, Marchuk DA, Vary CP and Bernabeu C: Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood 92: 4677-4690, 1998. (Pubitemid 29005870)
26. Graulich W, Nettelbeck DM, Fischer D, Kissel T and Muller R: Cell type specificity of the human endoglin promoter. Gene 227: 55-62, 1999.
27. Sanchez-Eisner T, Botella LM, Velasco B, Langa C and Bernabeu C: Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 277: 43799-43808, 2002. (Pubitemid 36157800)
28. Ota T, Fujii M, Sugizaki T, Ishii M, Miyazawa K, Aburatani H and Miyazono K: Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J Cell Physiol 193: 299-318, 2002.
29. Li C, Guo B, Ding S, Rius C, Langa C, Kumar P, Bernabeu C and Kumar S: TNF alpha down-regulates CD105 expression in vascular endothelial cells: a comparative study with TGF beta 1. Anticancer Res 23: 1189-1196, 2003. (Pubitemid 36754077)
30. Cho SK, Bourdeau A, Letarte M and Zuniga-Pflucker JC: Expression and function of CD105 during the onset of hematopoiesis from Flk1(+) precursors. Blood 98: 3635-3642, 2001.
31. Gougos A, St Jacques S, Greaves A, O'Connell PJ, d'Apice AJ, Buhring HJ, Bernabeu C, van Mourik JA and Letarte M: Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol 4: 83-92, 1992.
32. Lastres P, Bellon T, Cabanas C, Sanchez-Madrid F, Acevedo A, Gougos A, Letarte M and Bernabeu C: Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 22: 393-397, 1992.
33. Rokhlin OW, Cohen MB, Kubagawa H, Letarte M and Cooper MD: Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol 154: 4456-4465, 1995.
34. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J and Hunter RD: A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 54: 363-370, 1993. (Pubitemid 23169671)
35. Takase Y, Kai K, Masuda M, Akashi M and Tokunaga O: Endoglin (CD105) expression and angiogenesis status in small cell lung cancer. Pathol Res Pract 206: 725-730, 2010.
36. Blobe GC, Schiemann WP and Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350-1358, 2000.
37. Govinden R and Bhoola KD: Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol Ther 98: 257-265, 2003. (Pubitemid 36513779)
38. Zhu HJ and Burgess AW: Regulation of transforming growth factor-beta signaling. Mol Cell Biol Res Commun 4: 321-330, 2001.
39. Hata A, Shi Y and Massague J: TGF-beta signaling and cancer: structural and functional consequences of mutations in Smads. Mol Med Today 4: 257-262, 1998.
40. Pepper MS: Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 8: 21-43, 1997.
41. Barbara NP, Wrana JL and Letarte M: Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 274: 584-594, 1999.
42. Massague J and Wotton D: Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19: 1745-1754, 2000. (Pubitemid 30204386)
43. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, Mummery C, Arthur HM and ten Dijke P: Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23: 4018-4028, 2004.
44. Goumans MJ, Liu Z and ten Dijke P: TGF-beta signaling in vascular biology and dysfunction. Cell Res 19: 116-127, 2009.
45. Ray BN, Lee NY, How T and Blobe GC: ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration. Carcinogenesis 31: 435-441, 2010.
46. Romero D, Terzic A, Conley BA, Craft CS, Jovanovic B, Bergan RC and Vary CP: Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. Carcinogenesis 31: 359-366, 2010.
47. Lastres P, Letamendia A, Zhang H, Rius C, Almendro N, Raab U, Lopez LA, Langa C, Fabra A, Letarte M and Bernabeu C: Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 133: 1109-1121, 1996. (Pubitemid 26172515)
48. Letamendia A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, Attisano L and Bernabeu C: Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem 275: 33011-33019, 1998. (Pubitemid 28557696)
49. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C and Kumar S: CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J 14: 55-64, 2000. (Pubitemid 30051523)
50. Jerkic M, Rivas-Elena JV, Prieto M, Carron R, Sanz-Rodriguez F, Perez-Barriocanal F, Rodriguez-Barbero A, Bernabeu C and Lopez-Novoa JM: Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J 18: 609-611, 2004.
51. Jerkic M, Rodriguez-Barbero A, Prieto M, Toporsian M, Pericacho M, Rivas-Elena JV, Obreo J, Wang A, Perez-Barriocanal F, Arevalo M, Bernabeu C, Letarte M and Lopez-Novoa JM: Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovasc Res 69: 845-854, 2006. (Pubitemid 43227983)
52. Alev C, McIntyre BA, Ota K and Sheng G: Dynamic expression of Endoglin, a TGF-beta co-receptor, during pre-circulation vascular development in chick. Int J Dev Biol 54: 737-742, 2010.
53. Haitjema T, Westermann CJ, Overtoom TT, Timmer R, Disch F, Mauser H and Lammers JW: Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): new insights in pathogenesis, complications, and treatment. Arch Intern Med 156: 714-719, 1996. (Pubitemid 26108192)
54. Mahmoud M, Allinson KR, Zhai Z, Oakenfull R, Ghandi P, Adams RH, Fruttiger M and Arthur HM: Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ Res 106: 1425-1433, 2010.
55. Paquet ME, Pece-Barbara N, Vera S, Cymerman U, Karabegovic A, Shovlin C and Letarte M: Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function. Hum Mol Genet 10: 1347-1357, 2001. (Pubitemid 32640663)
56. Pece-Barbara N, Cymerman U, Vera S, Marchuk DA and Letarte M: Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. Hum Mol Genet 82171-82181, 1999.
57. Bourdeau A, Dumont DJ and Letarte M: A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104: 1343-1351, 1999.
58. Bourdeau A, Faughnan ME, McDonald ML, Paterson AD, Wanless IR and Letarte M: Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol 158: 2011-2020, 2001.
59. Griffioen AW and Molema G: Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52: 237-268, 2000. (Pubitemid 30368433)
60. Folkman J, Watson K, Ingber D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61, 1989. (Pubitemid 19115892)
61. Maier JA, Delia D, Thorpe PE and Gasparini G: In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. Anticancer Drugs 8: 238-244, 1997.
62. Choi KS, Bae MK, Jeong JW, Moon HE and Kim KW: Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol 36: 120-127, 2003.
63. Tian F, Zhou AX, Smits AM, Larsson E, Goumans MJ, Heldin CH, Boren J and Akyurek LM: Endothelial cells are activated during hypoxia via endoglin/ALK-1/SMAD1/5 signaling in vivo and in vitro. Biochem Biophys Res Commun 392: 283-288, 2010.
64. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ and Ellis LM: Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 14: 1931-1937, 2008.
65. 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int J Cancer 109: 436-441, 2004. (Pubitemid 38252774)
66. Bredow S, Lewin M, Hofmann B, Marecos E and Weissleder R: Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer 36: 675-681, 2000. (Pubitemid 30156855)
67. Duff SE, Li C, Garland JM and Kumar S: CD105 is important for angiogenesis: evidence and potential applications. FASEB J 17: 984-992, 2003. (Pubitemid 36676386)
68. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K and Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120-1124, 1992.
69. Srivastava A, Laidler P, Davies RP, Horgan K and Hughes LE: The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol 133: 419-423, 1988. (Pubitemid 19017504)
70. Tanigawa N, Amaya H, Matsumura M and Shimomatsuya T: Association of tumour vasculature with tumour progression and overall survival of patients with non-early gastric carcinomas. Br J Cancer 75: 566-571, 1997. (Pubitemid 27085301)
71. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S and Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992.
72. Page DL and Jensen RA: Angiogenesis in human breast carcinoma: What is the question? Hum Pathol 26: 1173-1174, 1995.
73. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL and Dirix LY: Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A: 2474-2484, 1996.
74. Akagi K, Ikeda Y, Sumiyoshi Y, Kimura Y, Kinoshita J, Miyazaki M and Abe T: Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery 131(1 Suppl): S109-S113, 2002. (Pubitemid 34118625)
75. Behrem S, Zarkovic K, Eskinja N and Jonjic N: Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma. Croat Med J 46: 417-422, 2005. (Pubitemid 40686486)
76. Yao Y, Kubota T, Takeuchi H and Sato K: Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology 25: 201-206, 2005.
77. Tabata M, Kondo M, Haruta Y and Seon BK: Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies. Int J Cancer 82: 737-742, 1999.
78. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K and Wada H: Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 7: 3410-3415, 2001. (Pubitemid 33069974)
79. Yao Y, Pan Y, Chen J, Sun X, Qiu Y and Ding Y: Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF. Ann Clin Lab Sci 37: 39-48, 2007. (Pubitemid 46350612)
80. Schimming R and Marme D: Endoglin (CD105) expression in squamous cell carcinoma of the oral cavity. Head Neck 24: 151-156, 2002.
81. Brewer CA, Setterdahl JJ, Li MJ, Johnston JM, Mann JL and McAsey ME: Endoglin expression as a measure of microvessel density in cervical cancer. Obstet Gynecol 96: 224-228, 2000. (Pubitemid 30447343)
82. Pizarro CB, Oliveira MC, Pereira-Lima JF, Leaes CG, Kramer CK, Schuch T, Barbosa-Coutinho LM and Ferreira NP: Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker. Neuropathology 29: 40-44, 2009.
83. Ho JW, Poon RT, Sun CK, Xue WC and Fan ST: Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver. World J Gastroenterol 11: 176-181, 2005. (Pubitemid 40125199)
84. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H and Seon BK: Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 7: 524-532, 2001. (Pubitemid 32707974)
85. Mysliwiec P, Pawlak K, Kuklinski A and Kedra B: Combined perioperative plasma endoglin and VEGF - a assessment in colorectal cancer patients. Folia Histochem Cytobiol 47: 231-236, 2009.
86. Marioni G, D'Alessandro E, Giacomelli L and Staffieri A: CD105 is a marker of tumour vasculature and a potential target for the treatment of head and neck squamous cell carcinoma. J Oral Pathol Med 39: 361-367, 2010.
87. Cohen MH, Gootenberg J, Keegan P and Pazdur R: FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12: 713-718, 2007.
88. Cohen MH, Gootenberg J, Keegan P and Pazdur R: FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12: 356-361, 2007. (Pubitemid 46556802)
89. Ferrara N: VEGF as a therapeutic target in cancer. Oncology 69(Suppl): 11-16, 2005.
90. Ferrara N, Hillan KJ and Novotny W: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333: 328-335, 2005. (Pubitemid 40848295)
91. Duwel A, Eleno N, Jerkic M, Arevalo M, Bolanos JP, Bernabeu C and Lopez-Novoa JM: Reduced tumor growth and angiogenesis in endoglin- haploinsufficient mice. Tumour Biol 28: 1-8, 2007. (Pubitemid 46012460)
92. Korn T, Muller R and Kontermann RE: Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J Immunother 27: 99-106, 2004. (Pubitemid 38282729)
93. Ahmadvand D, Rasaee MJ, Rahbarizadeh F and Mohammadi M: Production and characterization of a high-affinity nanobody against human endoglin. Hybridoma (Larchmt) 27: 353-360, 2008.
94. Volkel T, Holig P, Merdan T, Muller R and Kontermann RE: Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 1663: 158-166, 2004. (Pubitemid 38625590)
95. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M and Seon BK: Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 5: 371-382, 1999.
96. Seon BK, Matsuno F, Haruta Y, Kondo M and Barcos M: Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 3: 1031-1044, 1997.
97. Takahashi N, Haba A, Matsuno F and Seon BK: Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 61: 7846-7854, 2001. (Pubitemid 33049374)
98. Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, Tsai H and Seon BK: Antitumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer 122: 2266-2273, 2008. (Pubitemid 351542330)
99. Tsujie M, Uneda S, Tsai H and Seon BK: Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites. Int J Oncol 29: 1087-1094, 2006.
100. Uneda S, Toi H, Tsujie T, Tsujie M, Harada N, Tsai H and Seon BK: Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 125: 1446-1453, 2009.
101. Tan GH, Huang FY, Wang H, Huang YH, Lin YY and Li YN: Immunotherapy of hepatoma with a monoclonal antibody against murine endoglin. World J Gastroenterol 13: 2479-2483, 2007. (Pubitemid 46929504)
102. Mendelson DA, Gordon MS, Rosen LS, Hurwitz H, Wong MK, Adams BJ, Alvarez D, Seon BK, Theuer CP and Leigh BR: Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients with advanced refractory cancer. J Clin J Clin Oncol 28 (Suppl): 15s, Abstract 3013, 2010.
103. Bloemendal HJ, Logtenberg T and Voest EE: New strategies in anti-vascular cancer therapy. Eur J Clin Invest 29: 802-809, 1999. (Pubitemid 29425522)
104. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.